1111OCisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC)
Jones, D A, Mehanna, H, Mistry, P, Dalby, M, Fulton-Lieuw, T, Kong, A H, Dunn, J, Gray, AVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz252.003
Date:
October, 2019
Fichier:
PDF, 88 KB
2019
File converter
Plus de résultats de recherche
More benefits 
